口腔乾燥症治療薬市場- 世界の産業規模、シェア、動向、機会、予測、2018年-2028年タイプ別、製品別、地域別、競合予測・市場競合、2018年-2028年セグメント別

口腔乾燥症治療薬の世界市場規模は2022年に19億8,000万米ドルとなり、2028年までのCAGRは3.69%で、予測期間中に目覚ましい成長を遂げると予測されています。

がん治療における化学療法や放射線療法の採用が増加していることに加え、処方される薬剤の使用量が増加していることから、市場の成長は大きく伸びると予想されます。口腔乾燥症は、唾液分泌の減少に起因する口腔内の乾燥を特徴とし、口の乾燥感、口腔内のほてり、嚥下困難、味覚の低下や喪失を引き起こす可能性があります。唾液腺は化学療法や放射線療法によって損傷を受け、その結果ドライマウスになります。腫瘍内科医や開業医が行う最も一般的ながん治療である化学療法では、副作用として口腔乾燥が生じることが多いです。さらに、口腔乾燥症は薬物療法、頭頸部放射線療法、化学療法、さらにはシェーグレン症候群によっても引き起こされることがあります。2016年1月1日現在、米国がん協会によると、米国では350万人の女性が乳がんと共存しています。ステージIV乳がんの女性のうち、48％が治療の一環として放射線療法および/または化学療法を受けています。

市場促進要因

口腔乾燥を引き起こす疾患の発生率の増加

口腔乾燥症は、一般にドライマウスとして知られ、唾液の流量の減少を特徴とする一般的な疾患です。口腔乾燥症は些細な不都合のように思われるかもしれないが、個人のQOLに重大な影響を及ぼし、会話や食事、さらには食事を楽しむ能力にまで影響を及ぼす可能性があります。世界の口腔乾燥症治療薬市場は著しい成長を遂げているが、この市場拡大の主な要因のひとつは、口腔乾燥を引き起こす疾患の発生率が増加していることです。口腔乾燥を引き起こす疾患の発生率増加の主な要因はがんです。化学療法と放射線療法は、がんの一般的な治療法であるが、しばしば唾液腺にダメージを与え、ドライマウスを引き起こします。世界のがん罹患率の上昇に伴い、これらの治療の副作用として口腔乾燥を経験する患者数も増加しています。このため、ドライマウスの緩和を求める患者が大量に発生し、口腔乾燥症治療薬の需要を牽引しています。世界の人口は高齢化しており、高齢者の割合はかつてないほど高くなっています。高齢になると、薬物療法を必要とする複数の健康問題が発生する傾向があります。これらの薬剤の多くは、副作用として口腔乾燥症を伴う。高齢者がより多くの薬を服用するようになったことで、この層におけるドライマウスの有病率は増加傾向にあります。この人口動態の変化は口腔乾燥症治療薬市場の成長に大きく寄与しています。ポリファーマシー（一個人が複数の薬剤を同時に使用すること）は、ますます一般的になりつつあります。慢性的な健康状態にある人は、病気を管理するために複数の薬剤を服用することが多く、その結果、副作用として口腔乾燥症を経験する可能性が高くなります。この現象は、口腔乾燥症状を緩和する効果的な解決策を必要とする患者が増えるにつれて、口腔乾燥症治療薬に対する需要を増幅させています。主に唾液腺と涙腺に影響を及ぼす自己免疫疾患であるシェーグレン症候群のような状態は、慢性的なドライマウスにつながる可能性があります。自己免疫疾患の有病率は増加傾向にあり、口腔乾燥症を経験する人の数に直接的な影響を与えています。これらの疾患に対する認識が高まり、より多くの患者が診断されるにつれ、口腔乾燥症治療薬に対する需要は増加の一途をたどっています。ヘルスケア専門家は口腔乾燥症の診断に習熟し、重大な健康上の懸念として認識するようになってきています。この診断と報告の改善により、口渇症状の治療を求める患者が増え、口腔乾燥症治療薬市場をさらに強化しています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 口腔乾燥症治療薬の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別（OTC、処方薬）
  • 製品別（唾液分泌促進剤、唾液代用品、歯磨剤）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ
  • タイプ別
  • 製品別
  • 地域別

第6章 北米口腔乾燥症治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 製品別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州口腔乾燥症治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 製品別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋口腔乾燥症治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 製品別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米口腔乾燥症治療薬市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 製品別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカ口腔乾燥症治療薬市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 製品別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Acacia Pharma Ltd
• Parnell Pharmaceuticals Holdings Ltd
• Pfizer Inc
• GSK PLC
• Church & Dwight Co Inc
• Lupin Pharmaceuticals Inc
• Sun Pharmaceutical Industries Ltd
• Hikma Pharmaceuticals PLC.
• Pendopharm Inc
• OraCoat

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Xerostomia Therapeutics Market has valued at USD 1.98 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 3.69% through 2028. The market growth is expected to receive a significant boost due to the increasing adoption of chemotherapy and radiotherapy for cancer treatment, along with the rising use of prescribed medications. Xerostomia, characterized by oral dryness resulting from reduced saliva production, can lead to sensations of mouth dryness, oral burning, difficulty in swallowing, and a decrease or loss of taste. The salivary glands are damaged by chemotherapy and radiation therapy, resulting in dry mouth. Chemotherapy, the most common cancer treatment provided by oncologists and medical practitioners, often leads to xerostomia as a side effect. Additionally, xerostomia can be caused by medication, head and neck radiation therapy, chemotherapy, and even Sjogren's syndrome. As of January 1, 2016, the American Cancer Society reported that 3.5 million women in the U.S. were living with breast cancer. Among women with stage IV breast cancer, 48% received radiation and/or chemotherapy as part of their treatment.

Key Market Drivers

Increasing Incidence of Xerostomia-Causing Conditions

Xerostomia, commonly known as dry mouth, is a prevalent condition characterized by a reduced flow of saliva. While it may seem like a minor inconvenience, xerostomia can have a significant impact on an individual's quality of life, affecting their ability to speak, eat, and even enjoy food. The global xerostomia therapeutics market is experiencing remarkable growth, and one of the key drivers behind this expansion is the increasing incidence of xerostomia-causing conditions. Cancer is a major contributor to the increasing incidence of xerostomia-causing conditions. Chemotherapy and radiation therapy, two common treatments for cancer, often lead to damage to the salivary glands, resulting in dry mouth. As the global cancer burden continues to rise, the number of patients experiencing xerostomia as a side effect of these treatments is also increasing. This creates a substantial patient pool seeking relief from dry mouth, thus driving the demand for xerostomia therapeutics. The world's population is aging, with a higher proportion of elderly individuals than ever before. As people age, they tend to develop multiple health issues that require medication. Many of these medications have xerostomia as a side effect. With the elderly population taking more medications, the prevalence of dry mouth among this demographic is on the rise. This demographic shift significantly contributes to the growth of the xerostomia therapeutics market. Polypharmacy, the concurrent use of multiple medications by an individual, is becoming increasingly common. People with chronic health conditions often take multiple drugs to manage their ailments, which can increase the likelihood of experiencing xerostomia as a side effect. This phenomenon amplifies the demand for xerostomia therapeutics as more patients require effective solutions to alleviate dry mouth symptoms. Conditions like Sjogren's syndrome, an autoimmune disease that primarily affects the salivary and tear glands, can lead to chronic dry mouth. The prevalence of autoimmune diseases is on the rise, and this has a direct impact on the number of individuals experiencing xerostomia. As awareness of these diseases grows and more patients are diagnosed, the demand for xerostomia therapeutics continues to increase. Healthcare professionals are becoming more adept at diagnosing xerostomia and recognizing it as a significant health concern. This improved diagnosis and reporting have led to more patients seeking treatment for their dry mouth symptoms, further bolstering the xerostomia therapeutics market.

Advances in Xerostomia Therapeutics

Xerostomia, commonly referred to as dry mouth, is a condition characterized by insufficient saliva production, leading to discomfort and potential oral health complications. It affects millions of individuals worldwide and can be caused by various factors, including medication, radiation therapy, and systemic diseases. The global xerostomia therapeutics market is witnessing significant growth, primarily due to continuous advancements in treatment options. One of the most prominent factors contributing to the growth of the xerostomia therapeutics market is the development of innovative medications specifically designed to combat dry mouth. Pharmaceutical companies are investing in research and development to create drugs that stimulate salivary gland function or mimic the properties of saliva. These breakthrough medications offer patients more effective and targeted relief from xerostomia symptoms. Advances in the formulation of saliva substitutes have provided patients with viable alternatives to natural saliva. These substitutes aim to replicate the properties of saliva, such as lubrication and pH balance, to alleviate dry mouth symptoms effectively. As these products become more sophisticated and accessible, they contribute significantly to the growth of the xerostomia therapeutics market. Biotechnology plays a crucial role in the development of xerostomia therapeutics. Researchers are exploring biotechnological approaches to stimulate saliva production and improve the overall oral health of individuals suffering from dry mouths. These innovations offer promising solutions and enhance the market's potential for growth. Advances in healthcare technology enable the customization of xerostomia treatment plans for individual patients. With the availability of personalized therapies, healthcare providers can tailor interventions to the unique needs and preferences of each patient. This tailored approach not only enhances patient satisfaction but also drives demand for xerostomia therapeutics. Drug delivery systems have evolved significantly, making it easier for patients to administer xerostomia therapeutics. Improved formulations, such as oral sprays, gels, and lozenges, offer convenience and more effective delivery of medications or substitutes, further boosting patient compliance and market growth. Advances in patient education and awareness campaigns have led to increased recognition of the importance of managing xerostomia. As more individuals become aware of the available treatment options, they are likely to seek out therapies that provide relief from dry mouth symptoms, driving market expansion.

Growing Awareness and Diagnosis Rates

Xerostomia, more commonly known as dry mouth, is a condition characterized by a reduced production of saliva, which can result in significant discomfort and oral health issues. It is caused by various factors, including medication, radiation therapy, and certain medical conditions. The global xerostomia therapeutics market is on a growth trajectory, largely driven by the increasing awareness of this condition among both patients and healthcare professionals, as well as the improved rates of diagnosis. One of the key factors driving the growth of the xerostomia therapeutics market is the increasing emphasis on patient education. Healthcare organizations, advocacy groups, and pharmaceutical companies are actively engaged in educational campaigns to raise awareness about xerostomia. Patients are now better informed about the condition's symptoms and consequences, which leads to a higher likelihood of seeking medical assistance and treatment. Healthcare professionals, including dentists, oncologists, and primary care physicians, are becoming more proficient in recognizing xerostomia. They are now better equipped to identify the condition's signs during routine examinations and consultations. As a result, patients are being diagnosed more accurately and promptly, leading to an increased demand for xerostomia therapeutics. Xerostomia is often a symptom of underlying health conditions, such as Sjogren's syndrome or diabetes. As awareness of these conditions grows, so does the recognition of xerostomia as a related concern. Patients with these underlying conditions are more likely to be screened for dry mouth, thus contributing to increased diagnosis rates and the demand for appropriate therapeutics. The internet and various media outlets have played a significant role in disseminating information about xerostomia. Patients can easily access information about the condition's causes, symptoms, and available treatments. This ease of access empowers individuals to seek help and inquire about xerostomia therapeutics during medical appointments. The development of improved diagnostic tools and techniques has facilitated the identification of xerostomia. Salivary flow tests, imaging, and other diagnostic methods have become more precise, allowing healthcare providers to diagnose dry mouth more accurately. This, in turn, drives the demand for xerostomia therapeutics.

Research and Development Efforts

Xerostomia, commonly known as dry mouth, is a medical condition characterized by a lack of saliva production in the mouth. This condition can be caused by various factors, including medication side effects, medical treatments, and underlying health conditions. Xerostomia not only affects the comfort and quality of life for those who suffer from it but also poses potential risks to oral health. As the global population ages and the prevalence of xerostomia continues to rise, there is a pressing need for effective therapeutic solutions. Research and development (R&D) efforts play a pivotal role in addressing this need and driving the growth of the global xerostomia therapeutics market. Xerostomia is not merely an inconvenience but a condition that can have far-reaching consequences. Saliva plays a crucial role in maintaining oral health by helping to digest food, neutralizing acids, and preventing tooth decay. The xerostomia therapeutics market is poised for significant growth, primarily due to the aging population and the rising prevalence of conditions such as Sjogren's syndrome, diabetes, and cancer, which are known to cause dry mouth. R&D endeavors can lead to the development of innovative therapies tailored to address the specific causes and symptoms of xerostomia. These may include pharmaceuticals, biologics, and advanced oral care products. Research can help identify biomarkers and genetic factors that contribute to xerostomia. This knowledge can pave the way for personalized treatment approaches, ensuring better outcomes for patients. R&D allows for rigorous clinical trials and studies that evaluate the safety and efficacy of xerostomia therapies. This data is vital for gaining regulatory approvals and building trust among healthcare providers and patients. R&D efforts can also contribute to increased awareness and education about xerostomia among both healthcare professionals and the general public, leading to earlier diagnosis and treatment. As new and improved xerostomia therapies emerge, the global market for these treatments is expected to expand significantly. This growth not only benefits pharmaceutical companies but also creates opportunities for healthcare professionals and patients alike. To harness the full potential of R&D in boosting the xerostomia therapeutics market, collaboration between pharmaceutical companies, research institutions, healthcare providers, and patient advocacy groups is essential. This synergy can expedite the development of promising therapies and ensure they reach the market sooner. Investment in R&D is equally crucial. Governments, private investors, and philanthropic organizations can play a pivotal role in funding research initiatives focused on xerostomia. These investments can help accelerate breakthroughs and reduce the time it takes for new treatments to become available to those in need.

Key Market Challenges

Limited Understanding of Xerostomia Causes

One of the primary challenges in the xerostomia therapeutics market is the limited understanding of the diverse causes of dry mouth. While some cases are medication-induced, others result from medical treatments or underlying health conditions. Identifying the exact cause of xerostomia in each patient is essential for tailoring effective treatments. The lack of comprehensive knowledge can lead to misdiagnoses and ineffective therapies.

Complexity of Treatment Approaches

Xerostomia is a multifaceted condition with numerous contributing factors. Developing effective treatments that address these complexities is challenging. Traditional approaches often focus on symptomatic relief, such as saliva substitutes or stimulants. However, addressing the root causes of xerostomia, such as salivary gland dysfunction or autoimmune diseases like Sjogren's syndrome, requires innovative and personalized therapies. These approaches can be expensive and time-consuming to develop.

Patient Compliance and Adherence

Even when effective treatments are available, patient compliance and adherence can be problematic. Xerostomia may be a chronic condition, and patients may need to use therapies consistently for prolonged periods. Overcoming the inconvenience and potential side effects of treatments can be a barrier to patient adherence, reducing treatment efficacy.

Cost of Therapies

Some xerostomia therapeutics, particularly novel and innovative treatments, can be costly. This cost can be a significant burden for patients, particularly when treatments are not covered by insurance or healthcare systems. Access to affordable therapies is crucial for ensuring that xerostomia patients receive the care they need.

Key Market Trends

Personalized Medicine and Biomarker Development

One of the most promising trends in the xerostomia therapeutics market is the move towards personalized medicine. Researchers are actively identifying biomarkers and genetic factors that contribute to xerostomia. This allows for tailoring treatments to individual patients, increasing treatment efficacy, and minimizing side effects. By understanding the unique genetic and physiological aspects of each patient, healthcare providers can prescribe treatments that are more likely to succeed.

Innovative Drug Formulations

Innovations in drug formulation are paving the way for more convenient and effective xerostomia treatments. Recent developments include novel drug delivery systems such as mouth sprays, gels, and mucoadhesive patches. These formulations aim to provide longer-lasting relief, enhance patient compliance, and improve the overall treatment experience.

Digital Health Solutions

The integration of digital health solutions is transforming the way xerostomia is managed. Mobile apps, wearable devices, and telehealth platforms are being developed to help patients monitor their oral health, track medication adherence, and receive real-time guidance from healthcare professionals. These digital tools not only empower patients but also enable remote monitoring and data-driven treatment adjustments.

Natural and Herbal Remedies

Consumer interest in natural and herbal remedies is influencing the xerostomia therapeutics market. Several herbal products and natural supplements are gaining popularity for their potential to alleviate dry mouth symptoms. Research is ongoing to validate the safety and efficacy of these remedies, which could provide alternative options for patients seeking holistic approaches to managing xerostomia.

Segmental Insights

Type Insights

Based on the category of Type, the market can be divided into two segments: Over-the-Counter (OTC) and prescription. In 2022, the OTC segment held the largest market share, and it is anticipated to exhibit significant growth at a favorable compound annual growth rate (CAGR) throughout the projected period. This dominance can be attributed to several factors, including the wide range of available products, their safety and effectiveness, the presence of limited branded drugs, and competitive pricing.

OTC products represent the primary approach for addressing xerostomia, and for most cases of xerostomia, these products are sufficient and pose no complications. In instances of severe xerostomia, prescription medications may be necessary. Through proper care and medication, xerostomia can be effectively managed and controlled, thereby preventing any potential complications.

Product Insights

The market can be segmented based on product into salivary stimulants, salivary substitutes, and dentifrices. In 2022, the salivary stimulants segment was the market leader. Salivary stimulants are substances designed to enhance the production of saliva and can be further categorized as pharmacological (affecting the nervous system) or non-pharmacological (influencing taste buds or chewing muscles). They come in various forms, including mints, sugar-free chewing gums, sprays, and lozenges. In November 2018, 3M introduced the Xerostomia Relief Spray, which provides relief for up to 4 hours by moistening and lubricating mucosa. In September 2021, ICPA Health Products Ltd. launched Wet Mouth, a saliva substitute based on sodium carboxymethyl cellulose, designed to treat xerostomia and reduce surface abrasion.

The dentifrices segment is projected to experience the most rapid growth in terms of CAGR during the forecast period. Dentifrices are specialized dental cleaning agents, powders, or pastes that help alleviate dry mouth by eliminating irritants that contribute to dryness. GC America Inc.'s MI Paste and MI Paste Plus are products that can be applied to the teeth to stimulate saliva production and restore essential saliva components such as calcium and phosphate.

Regional Insights

In 2022, the North American region emerged as the dominant player in the market. The primary factors contributing to this dominance include the growing prevalence of conditions like xerostomia and related ailments such as Sjogren's syndrome and rheumatoid arthritis. Additionally, the increasing awareness campaigns focused on dry mouth have played a pivotal role in this dominance. Notably, the Sjogren's Foundation's "April is Sjogren's Awareness Month" campaign has significantly contributed to raising awareness about Sjogren's syndrome.

Looking ahead, the Asia Pacific region is expected to exhibit the most rapid CAGR during the forecast period. This growth can be attributed to several key factors, including the escalation in healthcare expenditure, heightened awareness campaigns, and a rising incidence of conditions like diabetes, cancer, and Parkinson's disease. According to a study conducted by the National Institutes of Health (NIH), between 1990 and 2019, the occurrences of Parkinson's disease witnessed substantial increases in East Asia, South Asia, Southeast Asia, and Central Asia, with growth rates of 202.22%, 204.06%, 164.21%, and 67.93%, respectively.

Key Market Players

Acacia Pharma Ltd

Parnell Pharmaceuticals Holdings Ltd

Pfizer Inc

GSK PLC

Church & Dwight Co Inc

Lupin Pharmaceuticals Inc

Sun Pharmaceutical Industries Ltd

Hikma Pharmaceuticals PLC.

Pendopharm Inc

OraCoat

Report Scope:

In this report, the Global Xerostomia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xerostomia Therapeutics Market, By Type:

• OTC
• Prescription

Xerostomia Therapeutics Market, By Product:

• Salivary Stimulants
• Salivary Substitutes
• Dentifrices

Xerostomia Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Xerostomia Therapeutics Market.

Available Customizations:

• Global Xerostomia Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Xerostomia Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (OTC, Prescription)
  • 5.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By Product
  • 5.3.3. By Region

6. North America Xerostomia Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (OTC, Prescription)
  • 6.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Xerostomia Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
  • 6.3.2. Canada Xerostomia Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
  • 6.3.3. Mexico Xerostomia Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product

7. Europe Xerostomia Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (OTC, Prescription)
  • 7.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Xerostomia Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
  • 7.3.2. United Kingdom Xerostomia Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
  • 7.3.3. France Xerostomia Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
  • 7.3.4. Italy Xerostomia Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
  • 7.3.5. Spain Xerostomia Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product

8. Asia-Pacific Xerostomia Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (OTC, Prescription)
  • 8.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Xerostomia Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
  • 8.3.2. Japan Xerostomia Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
  • 8.3.3. India Xerostomia Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
  • 8.3.4. Australia Xerostomia Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
  • 8.3.5. South Korea Xerostomia Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product

9. South America Xerostomia Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (OTC, Prescription)
  • 9.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Xerostomia Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
  • 9.3.2. Argentina Xerostomia Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
  • 9.3.3. Colombia Xerostomia Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product

10. Middle East and Africa Xerostomia Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (OTC, Prescription)
  • 10.2.2. By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Xerostomia Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
  • 10.3.2. Saudi Arabia Xerostomia Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
  • 10.3.3. UAE Xerostomia Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
  • 10.3.4. Kuwait Xerostomia Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By Product

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Acacia Pharma Ltd
  • 14.6.2. Parnell Pharmaceuticals Holdings Ltd
  • 14.6.3. Pfizer Inc
  • 14.6.4. GSK PLC
  • 14.6.5. Church & Dwight Co Inc
  • 14.6.6. Lupin Pharmaceuticals Inc
  • 14.6.7. Sun Pharmaceutical Industries Ltd
  • 14.6.8. Hikma Pharmaceuticals PLC.
  • 14.6.9. Pendopharm Inc
  • 14.6.10. OraCoat

15. Strategic Recommendations

16. About Us & Disclaimer